Q-omics provides the consensus-scored SARS1 profile across patient tissues and cancer cell-line models. SARS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SARS1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, SARS1 RNA expression shows 18,597 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where SARS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SARS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SARS1 survival associations across molecular data types. SARS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SARS1 RNA expression–survival associations across cancer types. High SARS1 expression shows unfavorable associations in HNSC, BLCA, KICH, ACC, LIHC and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SARS1 RNA expression.
This table summarizes SARS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SARS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SARS1 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, KIRC, HNSC and CHOL. The COAD box plot shows higher SARS1 RNA expression in tumor versus normal tissue (log2 FC = +0.433, t-test p < 0.001).
This table shows molecular features associated with SARS1 in patient tissues and cancer cell lines. In patient samples, SARS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SARS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
